Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
KP Tissue Inc. is a Canadian tissue products manufacturer operating primarily in the Quebec market through its Kruger Products partnership. The company produces private-label and branded tissue products (bathroom tissue, paper towels, napkins, facial tissue) for retail and away-from-home channels. With an extremely low EV/EBITDA of 1.4x and recent profitability inflection (49,000%+ net income growth), the stock trades as a deep-value turnaround play in a mature, commodity-like industry.
KP Tissue operates as a low-cost producer in the highly commoditized tissue manufacturing sector. Revenue generation depends on converting recycled fiber and virgin pulp into finished tissue products at scale. Profitability hinges on capacity utilization rates (typically 85-95% for tissue mills), input cost management (pulp represents 30-40% of COGS), and securing long-term supply agreements with major retailers. The business model emphasizes operational efficiency over brand premium - tissue products have minimal differentiation, making mill efficiency and logistics optimization critical. Limited pricing power exists due to intense private-label competition and retailer consolidation.
Pulp price volatility - Northern Bleached Softwood Kraft (NBSK) pulp pricing directly impacts 30-40% of input costs with 60-90 day lag
Capacity utilization rates at manufacturing facilities - breakeven typically 70-75% utilization, target 90%+
Natural gas and electricity pricing in Quebec operations - energy represents 15-20% of conversion costs
Retail channel inventory destocking/restocking cycles - tissue products face periodic retailer inventory adjustments
Canadian dollar weakness vs USD - benefits competitiveness against US imports, though most sales are domestic
Secular shift to recycled/sustainable fiber sources increases capital requirements - tissue manufacturers face pressure to convert mills from virgin pulp to recycled content, requiring $50-150M+ investments per line
Retail channel consolidation erodes pricing power - grocery consolidation (Loblaw, Metro, Sobeys control 60%+ of Canadian grocery) enables retailers to demand lower prices and shift to private label
E-commerce penetration in tissue products remains minimal but could disrupt traditional retail relationships if Amazon/online channels gain share
Intense competition from larger integrated players (Kruger Products parent, Irving Tissue, Cascades) with greater scale economies and vertical integration into pulp production
US tissue imports during periods of CAD strength - Canadian market faces import pressure from larger US mills (Georgia-Pacific, Kimberly-Clark) when currency unfavorable
Private label expansion by retailers threatens branded product mix - grocers increasingly launch premium private-label tissue lines
Extremely low market capitalization ($100M) creates liquidity risk - limited float and trading volume may prevent institutional accumulation
Lack of financial data transparency - zero reported revenue, cash flow, and margin metrics suggest either data reporting issues or potential going-concern questions
Pension and post-retirement benefit obligations common in legacy manufacturing - undisclosed liabilities could exist given unionized workforce typical in Canadian tissue mills
low - Tissue products are non-discretionary consumer staples with stable demand regardless of economic conditions. Away-from-home segment shows modest cyclicality tied to commercial real estate occupancy and hospitality activity, but represents minority of revenue. Retail tissue demand is recession-resistant, though consumers may trade down to lower-priced private label during downturns (potentially benefiting KP Tissue's private-label focus).
Moderate sensitivity through two channels: (1) Tissue manufacturing requires ongoing capex for mill maintenance and efficiency upgrades - higher rates increase project hurdle rates and reduce NPV of capital investments; (2) Consumer discretionary spending affects away-from-home tissue demand as businesses reduce office space and travel. However, the company's current zero debt/equity ratio eliminates direct financing cost exposure. Valuation multiples compress as rates rise given mature, low-growth industry profile.
Minimal direct credit exposure. The business operates with zero reported debt and maintains adequate liquidity (1.0x current ratio). Tissue manufacturing is capital-intensive but the company appears to have completed major capacity investments. Indirect credit risk exists through retail customer concentration - financial stress at major grocery chains could impact receivables, though tissue products typically receive priority payment as essential SKUs.
value - The stock exhibits classic deep-value characteristics: extremely low EV/EBITDA (1.4x vs industry average 8-10x), recent profitability inflection (49,000%+ net income growth suggests turnaround from losses), and 37.5% one-year return indicating value realization. However, lack of financial transparency and micro-cap status limit appeal to only the most specialized value/special situations investors. Not suitable for growth, income, or momentum strategies given mature industry and data limitations.
high - Micro-cap stocks with limited float exhibit elevated volatility regardless of business fundamentals. The 14.9% three-month return and 37.5% one-year return suggest significant price swings. Tissue manufacturing economics create operational leverage that amplifies earnings volatility from pulp price and volume fluctuations. Estimated beta likely 1.2-1.5x given small-cap premium and commodity input exposure.
